## Enantioselective β-C(sp<sup>3</sup>)–H arylation of amides via synergistic nickel and photoredox catalysis

Wu Zhang, <sup>a</sup> Xiaomin Shu, <sup>a</sup> Leitao Huan, <sup>a</sup> Buqing Cheng <sup>a</sup> and Haohua Huo <sup>\*a</sup>

Key Laboratory of Chemical Biology of Fujian Province, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, P. R. China

#### **Supporting Information**

#### **Table of Contents**

I.	General Information	S-2
II.	Preparation of chiral ligand (S)-L	S-3
III.	Effect of Reaction Parameters	S-4
IV.	Catalytic Enantioselective C(sp <sup>3</sup> )–H Arylation	S-5
V.	Assignment of Absolute Configuration	S-20
VI.	References	S-22
VII.	<sup>1</sup> H-NMR and <sup>13</sup> C-NMR Spectra; Stereoselectivity Analysis	S-23

#### I. General Information

Unless otherwise noted, reactions were performed with rigorous exclusion of air and moisture. N-Phenylpropanamide derivatives were prepared according to a literature procedure, and all analytical data matched that report.<sup>1</sup> Anhydrous EtOAc (>99.6%, Sigma-Aldrich) was dried using freshly activated 4Å MS. NiBr2·glyme (>97%, Strem), Na3PO4 (>96.0%, Sigma-Aldrich), and all starting materials and reagents were purchased from commercial sources and used as received. NMR spectra were collected on a Bruker 400 MHz, a Bruker 500 MHz spectrometer at ambient temperature. Chemical shifts ( $\delta$ ) are given in in parts per million (ppm) referenced to the appropriate solvent peak or 0.0 ppm for tetramethylsilane (<sup>1</sup>H NMR: CDCl<sub>3</sub> at 7.26 ppm. <sup>13</sup>C NMR: CDCl<sub>3</sub> at 77.00 ppm). The data are reported as follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet, dd = doublet of doublet, t = triplet, m = multiplet, br = broad), coupling constant J (Hz) and integration. HPLC analyses were carried out on an Agilent 1260 series system with Daicel CHIRALPAK® or Daicel CHIRALCEL® columns (4.6 × 250 mm, particle size 3 µm). FT-IR measurements were carried out on a Nicolet AVATER FTIR330 spectrometer. High resolution mass spectra (ESI) were recorded by the instrumentation center of Department of Chemistry, Xiamen University, on a high-resolution LC/MS instrument. Optical rotation data were obtained with an Anton Paar MCP 500 polarimeter at 589 nm and at 25 °C, using a 50 mm path-length cell in the solvent and at the concentration indicated. GC analyses were obtained on an Agilent 6890A GC. Blue LED lamps (40 W; Kessil PR160L) were used to irradiate the reaction mixtures. The chiral bisoxazoline,<sup>2-4</sup> bisimidazole,<sup>4</sup> and pydineoxazole ligands<sup>5</sup> are prepared according to the previously reported procedures. [Ir(dF(CF<sub>3</sub>)ppy)<sub>2</sub>)(dtbbpy)]PF<sub>6</sub> photocatalyst is synthesized by the previously reported method.<sup>6</sup>

#### **II.** Preparation of chiral ligand (S)-L



The synthesis of (S)-L was according to a similar procedure.<sup>2</sup> (S)-2-amino-2-cyclohexylethan-1-ol (2.0 equiv., 30 mmol, 4.3 g) and diethyl oxalate (1.0 equiv., 15 mmol, 2.0 mL) were dissolved in toluene (250 mL) and heated to 80 °C. The reaction was allowed to stir overnight with the diamide precipitating out of solution as a white solid. Reaction was cooled to room temperature and concentrated in vacuo. The crude diol was dissolved in toluene (150 mL) and heated to 70 °C whereupon thionyl chloride (2.0 equiv., 30 mmol, 2.4 mL) was added. Reaction was stirred at 70 °C for 30 minutes then heated to 90 °C for 2 h. The reaction was cooled to room temperature and poured into 20% KOH solution at 0 °C. The aqueous layer was separated and extracted three times with DCM and the combined organic layers were washed with 20% KOH solution, saturated NaHCO3 solution and brine. The organic layer was dried with Na2SO4, filtered, and concentrated under reduced pressure to afford the dichloro-intermediate as a sticky yellow solid. The crude dichloro-intermediate was immediately dissolved in MeOH (150 mL) and KOH (37.5 mmol, 2.1 g) was added. The reaction was heated to reflux for 14 hours. The reaction was cooled to room temperature and concentrated. The residue was purified by flash column chromatography (1:2 EtOAc/Petroleum ether) to give (S)-L (1.82 g, 6.0 mmol) in 40% yield as a white solid.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.46 – 4.37 (m, 2H), 4.19 – 4.01 (m, 4H), 1.96 (d, *J* = 12.9 Hz, 2H), 1.80 – 1.70 (m, 4H), 1.69 – 1.62 (m, 2H), 1.61 – 1.44 (m, 4H), 1.31 – 1.13 (m, 6H), 1.12 – 0.95 (m, 4H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 154.5, 72.3, 71.2, 42.3, 29.5, 28.9, 26.3, 25.88, 25.85.

FT-IR (film): 2920, 1654, 1613, 1451, 1356, 1106, 1069, 953, 716 cm<sup>-1</sup>.

HRMS (ESI-MS) *m*/*z* [M+Na]<sup>+</sup> calcd for C<sub>18</sub>H<sub>28</sub>N<sub>2</sub>O<sub>2</sub>Na: 327.2043, found: 327.2043.

#### **III.** Effect of Reaction Parameters

General Procedure A (GP-A): In a glovebox, Ir[dF(CF<sub>3</sub>)ppy]<sub>2</sub>(dtbbpy)PF<sub>6</sub> (1.1 mg, 0.001 mmol, 1%), NiBr2·glyme (3.1 mg, 0.01 mmol, 10%), (S)-L (4.0 mg, 0.013 mmol, 13%), Na3PO4 (24.6 mg, 0.15 mmol, 1.5 equiv), N,3-diphenylpropanamide (0.3 mmol, 3.0 equiv.), a Teflon stir bar, and anhydrous EtOAc (1.0 mL) were added sequentially to a 4-mL vial. The vial was closed with a PTFE septum cap and wrapped with electrical tape. After the reaction mixture was stirred at room temperature for 30 min, 4-bromobenzotrifluoride (14 µL, 0.10 mmol, 1.0 equiv) was added via a microsyringe. Next, the vial was transferred out of the glovebox, and then vacuum grease was liberally applied to cover the entrie top of the septum cap. Then, the reaction mixture was stirred at 10 °C in an EtOH bath for 1 min before being irradiated with a 40 W the blue LED lamp (Kessil PR160L, 427 nm, a single lamp was used for setup of two reactions as depicted below, and the distance between vials and the lamp is approximately 4cm.). The reaction was stirred under blue LED irradiation at 10 °C for 48 hours. Next, the lamp was turned off and the resulting mixture was allowed to warm to room temperature, and then dodecane (23 µL, 0.10 mmol) was added as an internal standard. The mixture was filtered through a small plug of silica gel, which was flushed with Et2O (~6 mL). A portion of the filtrate (0.1 mL) was diluted with acetone (total volume: ~1 mL) and analyzed via GC, and the remainder of the filtrate was concentrated via rotary evaporation, and the pure product was isolated by preparative TLC on silica gel (5:1 Dichloromethane/Petroleum ether).

The results for the effect of reaction parameters were shown in Fig. 1. **GP-A** was followed for the experiments set-up, using *N*,3-diphenylpropanamide (0.30 mmol) and 4-bromobenzotrifluoride (0.10 mmol), the yield was determined via GC analysis with dodecane as an internal standard. The ee values were determined via HPLC analysis after purification by preparative thin-layer chromatography.

#### IV. Catalytic Enantioselective C(sp<sup>3</sup>)-H Arylation

**General Procedure B (GP-B):** In a glovebox,  $Ir[dF(CF_3)ppy]_2(dtbbpy)PF_6$  (2.2 mg, 0.002mmol, 1%), NiBr<sub>2</sub>·glyme (6.2 mg, 0.02 mmol, 10%), (*S*)-L (8.0 mg, 0.026 mmol, 13%), Na<sub>3</sub>PO<sub>4</sub> (49.2 mg, 0.30 mmol, 1.5 equiv), Phenylpropanamide derivative (0.6 mmol, 3.0 equiv.), a Teflon stir bar, and anhydrous EtOAc (2.0 mL) was added sequentially to 4-mL vial. The vial was closed with a PTFE septum cap and wrapped with electrical tape. After the reaction mixture was stirred at room temperature for 30 min, aryl bromide (0.20 mmol, 1.0 equiv) was added. Next, the vial was transferred out of the glovebox, and then vacuum grease was liberally applied to cover the entire top of the septum cap. Then, the reaction mixture was stirred at 10 °C in an EtOH bath for 1 min before being irradiated with a 40 W the blue LED lamp (Kessil PR160L, 427 nm, a single lamp was used for setup of two reactions as depicted below, and the distance between vials and the lamp is approximately 4cm.). The reaction was stirred under blue LED irradiation at 10 °C for 48 hours. The reaction mixture was then passed through a short pad of silica gel, with Et<sub>2</sub>O as the eluent (~15 mL). The resulting mixture was concentrated, and the residue was purified by preparative thin-layer chromatography (PTLC) on silica gel.

**General Procedure C (GP-C):** Unless otherwise noted, the racemic products were synthesized according to **GP-A** except for changes in the following conditions: using dtbbpy (3.5 mg, 0.13 mmol, 13%) as ligand and the reaction was stirred for 16 hours under room temperature.



#### **Exemplary reaction setup:**



(*S*)-*N*,**3**-Diphenyl-3-(4-(trifluoromethyl)phenyl)propanamide (Figure 2, compound 1). The title compound was synthesized according to **GP-B** from *N*,3-diphenylpropanamide and 4-bromobenzotrifluoride. The product was purified by preparative thin-layer chromatography (PTLC) on silica gel (5:1 Dichloromethane/Petroleum ether). White solid.

(*S*)-L: 71 mg, 96% yield, 92% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 14.8 min (major), 20.6 min (minor).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.54 (d, *J* = 8.1 Hz, 2H), 7.38 (d, *J* = 8.0 Hz, 2H), 7.34 – 7.29 (m, 4H), 7.28 – 7.20 (m, 5H), 7.08 (t, *J* = 7.1 Hz, 1H), 7.03 (brs, 1H), 4.74 (t, *J* = 7.6 Hz, 1H), 3.16 – 3.02 (m, 2H).

<sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) δ –62.4 (s, 3F).

 $^{13}$ C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  169.0, 147.6, 142.6, 137.4, 128.9, 128.87, 128.88 (q,  $J_{\rm C-F}$  = 32.5 Hz), 128.0, 127.7, 127.0, 125.56 (q,  $J_{\rm C-F}$  = 3.7 Hz), 124.6, 124.10 (q,  $J_{\rm C-F}$  = 272.3 Hz), 120.2, 47.0, 43.7.

FT-IR (film): 3233, 2922, 1644, 1540, 1498, 1456, 1326, 1113, 1069, 743, 697 cm<sup>-1</sup>. HRMS (ESI-MS) m/z [M+H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>19</sub>F<sub>3</sub>NO: 370.1413, found:370.1414. [ $\alpha$ ]<sup>25</sup><sub>D</sub> = +0.5 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



(*S*)-3-(4-Cyanophenyl)-*N*,3-diphenylpropanamide (Figure 2, compound 2). The title compound was synthesized according to **GP-B** from *N*,3-diphenylpropanamide and 4-bromobenzonitrile. The product was purified by PTLC on silica gel (1:3 EtOAc/Petroleum ether). White solid.

(S)-L: 56 mg, 86% yield, 91% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (25.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 11.0 min (major), 16.3 min (minor).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.60 (brs, 1H), 7.50 (d, *J* = 7.8 Hz, 2H), 7.37 – 7.30 (m, 4H), 7.29 – 7.20 (m, 5H), 7.18 (d, *J* = 7.3 Hz, 2H), 7.07 (t, *J* = 7.2 Hz, 1H), 4.70 (t, *J* = 7.6 Hz, 1H), 3.04 (d, *J* = 7.6 Hz, 2H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.8, 149.2, 142.1, 137.4, 132.4, 128.9, 128.6, 127.6, 127.1, 124.5, 120.1, 118.8, 110.2, 47.1, 43.1.

FT-IR (film): 3307, 2929, 2227, 1658, 1599, 1545, 1498, 1442, 1308, 1066, 751, 693 cm<sup>-1</sup>. HRMS (ESI-MS) m/z [M+H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>19</sub>N<sub>2</sub>O: 327.1492, found: 327.1496. [ $\alpha$ ]<sup>25</sup><sub>D</sub> = -11.4 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



**Methyl** (*S*)-4-(3-oxo-1-phenyl-3-(phenylamino)propyl)benzoate (Figure 2, compound 3). The title compound was synthesized according to **GP-B** from *N*,3-diphenylpropanamide and methyl 4-bromobenzoate. The product was purified by PTLC on silica gel (1:3 EtOAc/Petroleum ether). White solid.

(S)-L: 62 mg, 87% yield, 91% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (25.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 10.5 min (major), 13.9 min (minor).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.92 (d, *J* = 8.4 Hz, 2H), 7.69 (brs, 1H), 7.32 (d, *J* = 7.8 Hz, 2H), 7.28 (d, *J* = 8.4 Hz, 2H), 7.26 – 7.20 (m, 4H), 7.20 – 7.15 (m, 3H), 7.04 (t, *J* = 7.3 Hz, 1H), 4.70 (t, *J* = 7.7 Hz, 1H), 3.86 (s, 3H), 3.04 (d, *J* = 7.7 Hz, 2H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.2, 167.0, 148.9, 142.7, 137.5, 129.9, 128.8, 128.7, 128.3, 127.8, 127.7, 126.8, 124.4, 120.2, 52.0, 47.1, 43.4.

FT-IR (film):3301, 3029, 2926, 1721, 1662, 1600, 1545, 1498, 1442, 1282, 1183, 754, 696 cm<sup>-1</sup>. HRMS (ESI-MS) m/z [M+H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>22</sub>NO<sub>3</sub>: 360.1594, found: 360.1595.  $[\alpha]^{25}_{D} = -3.5$  (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



(*S*)-3-(4-Acetylphenyl)-*N*,3-diphenylpropanamide (Figure 2, compound 4). The title compound was synthesized according to **GP-B** from *N*,3-diphenylpropanamide and 4'-bromoacetophenone. The product was purified by PTLC on silica gel (1:3 EtOAc/Petroleum ether). White solid.

(S)-L: 57 mg, 83% yield, 92% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (25.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 10.7 min (major), 15.7 min (minor). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.85 (d, *J* = 8.2 Hz, 2H), 7.60 (brs, 1H), 7.33 (d, *J* = 7.2 Hz, 4H), 7.30 – 7.24 (m, 3H), 7.23 – 7.17 (m, 4H), 7.05 (t, *J* = 7.3 Hz, 1H), 4.72 (t, *J* = 7.7 Hz, 1H), 3.08 (d, *J* = 7.7 Hz, 2H), 2.53 (s, 3H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 197.9, 169.0, 149.2, 142.7, 137.6, 135.5, 128.9, 128.8, 128.7, 128.0, 127.7, 126.9, 124.4, 120.1, 47.1, 43.5, 26.6.

FT-IR (film): 3321, 3053, 2923, 1734, 1668, 1600, 1544, 1498, 1443, 1269, 756, 700 cm<sup>-1</sup>.

HRMS (ESI-MS) *m*/*z* [M+H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>22</sub>NO<sub>2</sub>: 344.1645, found: 344.1648.

 $[\alpha]^{25}$ D = -2.8 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



(*S*)-3-(4-Chlorophenyl)-*N*,3-diphenylpropanamide (Figure 2, compound 5). The title compound was synthesized according to **GP-B** from *N*,3-diphenylpropanamide and 4-bromochlorobenzene. The product was purified by PTLC on silica gel (1:400 CH<sub>3</sub>OH/Dichloromethane). White solid.

(S)-L: 49 mg, 73% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 15.5 min (major), 19.2 min (minor).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36 – 7.30 (m, 4H), 7.29 – 7.23 (m, 7H), 7.22 – 7.18 (m, 2H), 7.15 – 7.06 (m, 2H), 4.66 (t, *J* = 7.6 Hz, 1H), 3.12 – 2.98 (m, 2H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.0, 143.0, 142.1, 137.4, 132.4, 129.1, 128.9, 128.8, 128.8, 127.7, 126.9, 124.5, 120.1, 46.6, 44.1.

FT-IR (film): 3238, 2926, 1641, 1595, 1534, 1488, 1446, 1281, 753, 696 cm<sup>-1</sup>. HRMS (ESI-MS) m/z [M+H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>19</sub>ClNO: 336.1150, found: 336.1153.  $[\alpha]^{25}D = +6.8$  (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



(*S*)-3-(3-Bromophenyl)-*N*,3-diphenylpropanamide (Figure 2, compound 6). The title compound was synthesized according to **GP-B** from *N*,3-diphenylpropanamide and 1,3-dibromobenzene. The product was purified by PTLC on silica gel (1:400 CH<sub>3</sub>OH/Dichloromethane). The corresponding racemic product was synthesized according to **GP-C** using (4*S*,4'*S*)-4,4'-diphenyl-4,4',5,5'-tetrahydro-2,2'-bioxazole as ligand instead. White solid.

(S)-L: 41 mg, 54% yield, 95% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 17.3 min (major), 22.9 min (minor).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.40 (s, 1H), 7.36 – 7.29 (m, 5H), 7.28 – 7.19 (m, 6H), 7.18 – 7.12 (m, 1H), 7.11 – 7.03 (m, 2H), 4.63 (t, *J* = 7.6 Hz, 1H), 3.04 (d, *J* = 7.6 Hz, 2H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.0, 145.9, 142.7, 137.4, 130.7, 130.2, 129.8, 128.9, 128.8, 127.7, 126.9, 126.5, 124.5, 122.7, 120.2, 46.9, 43.8.

FT-IR (film): 3293, 2923, 1655, 1599, 1544, 1498, 1443, 1311, 1257, 1074, 755, 701 cm<sup>-1</sup>. HRMS (ESI-MS) m/z [M+H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>19</sub>BrNO: 380.0645, found: 380.0648.  $[\alpha]^{25}_{D} = -0.5$  (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



(*S*)-3-(3-Methoxyphenyl)-*N*,3-diphenylpropanamide (Figure 2, compound 7). The title compound was synthesized according to **GP-B** from *N*,3-diphenylpropanamide and 3-bromoanisole. The product was purified by PTLC on silica gel (1:3 Acetone/Petroleum ether). White solid.

(S)-L: 41 mg, 62% yield, 92% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 18.8 min (major), 24.2 min (minor).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.31 – 7.23 (m, 6H), 7.23 – 7.17 (m, 3H), 7.11– 7.00 (m, 2H), 6.85 (d, *J* = 7.5 Hz, 1H), 6.81 (s, 1H), 6.74 (d, *J* = 8.2 Hz, 1H), 4.59 (t, *J* = 7.6 Hz, 1H), 3.73 (s, 3H), 3.04 (d, *J* = 7.6 Hz, 2H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.4, 159.8, 145.2, 143.4, 137.6, 129.7, 128.8, 128.7, 127.7, 126.7, 124.3, 120.07, 120.05, 113.9, 111.7, 55.1, 47.4, 44.3.

FT-IR (film): 3300, 3060, 2929, 1660, 1599, 1548, 1497, 1443, 1312, 1258, 1051, 755, 695 cm<sup>-1</sup>. HRMS (ESI-MS) m/z [M+H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>22</sub>NO<sub>2</sub>: 332.1645, found: 332.1647. [ $\alpha$ ]<sup>25</sup><sub>D</sub> = -0.1 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



(*S*)-3-(4-Phenoxyphenyl)-*N*,3-diphenylpropanamide (Figure 2, compound 8). The title compound was synthesized according to **GP-B** from *N*,3-diphenylpropanamide and 4-bromophenoxybenzene. The product was purified by PTLC on silica gel (1:400 CH<sub>3</sub>OH/Dichloromethane). White solid.

(S)-L: 42 mg, 53% yield, 86% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK **ID**-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 19.5 min (major), 21.8 min (minor).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.28 (t, *J* = 7.2 Hz, 6H), 7.26 – 7.17 (m, 7H), 7.10 – 7.02 (m, 2H), 6.95 (d, *J* = 8.0 Hz, 2H), 6.91 (d, *J* = 8.0 Hz, 2H), 4.62 (t, *J* = 7.6 Hz, 1H), 3.03 (d, *J* = 7.6 Hz, 2H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.4, 157.1, 155.9, 143.5, 138.3, 137.5, 129.7, 129.0, 128.9, 128.7, 127.7, 126.7, 124.4, 123.2, 120.1, 119.0, 118.8, 46.8, 44.4.

FT-IR (film): 3296, 2924, 1656, 1598, 1544, 1489, 1443, 1240, 1169, 753, 693 cm<sup>-1</sup>. HRMS (ESI-MS) *m*/*z* [M+H]<sup>+</sup> calcd for C<sub>27</sub>H<sub>24</sub>NO<sub>2</sub>: 394.1802, found: 394.1804.

 $[\alpha]^{25}_{D} = -14.4 \ (c \ 1.0, \ CH_2Cl_2).$ 



(*S*)-*N*,3-Diphenyl-3-(*m*-tolyl)propanamide (Figure 2, compound 9). The title compound was synthesized according to **GP-B** from *N*,3-diphenylpropanamide and 3-bromotoluene. The product was purified by PTLC on silica gel (1:400 CH<sub>3</sub>OH/Dichloromethane). White solid.

(*S*)-L: 27 mg, 44% yield, 89% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 12.4 min (minor), 14.3 min (major).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.33 – 7.22 (m, 7H), 7.22 – 7.15 (m, 2H), 7.11 – 6.99 (m, 4H), 6.94 (s, 1H), 4.58 (t, *J* = 7.6 Hz, 1H), 3.06 (d, *J* = 7.6 Hz, 2H), 2.29 (s, 3H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.5, 143.6, 143.4, 138.3, 137.5, 128.9, 128.7, 128.6, 128.6, 127.7, 127.5, 126.6, 124.6, 124.3, 120.1, 47.5, 44.4, 21.5.

FT-IR (film): 3294, 3026, 2922, 1659, 1600, 1548, 1498, 1443, 1311, 1175, 754, 698 cm<sup>-1</sup>. HRMS (ESI-MS) *m*/*z* [M+H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>22</sub>NO: 316.1696, found: 316.1700.

 $\frac{11}{1000} = \frac{1000}{1000} = \frac{1000}{1000} = \frac{10000}{1000} = \frac{1000}{1000} = \frac{10000}{1000} = \frac{10000}{1$ 

 $[\alpha]^{25}D = +3.1 (c \ 1.0, \ CH_2Cl_2).$ 



(*S*)-3-(Benzofuran-5-yl)-*N*,3-diphenylpropanamide (Figure 2, compound 10). The title compound was synthesized according to **GP-B** stirring for 63 h from *N*,3-diphenylpropanamide and 5-bromobenzofuran. The product was purified by PTLC on silica gel (1:3 Acetone/Petroleum ether). White solid.

(S)-L: 30 mg, 44% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 20.4 min (major), 24.4 min (minor).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.59 (d, *J* = 2.2 Hz, 1H), 7.50 (s, 1H), 7.42 (d, *J* = 8.5 Hz, 1H), 7.33 – 7.28 (m, 4H), 7.26 – 7.23 (m, 3H), 7.23 – 7.17 (m, 3H), 7.05 (t, *J* = 6.6 Hz, 1H), 6.96 (brs, 1H), 6.73 – 6.67(m, 1H), 4.75 (t, *J* = 7.7 Hz, 1H), 3.21 – 3.05 (m, 2H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.4, 153.8, 145.4, 143.9, 138.2, 137.5, 128.9, 128.7, 127.72, 127.68, 126.6, 124.34, 124.25, 120.06, 120.03, 111.5, 106.6, 47.3, 44.7.

FT-IR (film): 3293, 2924, 1659, 1600, 1541, 1498, 1443, 1258, 1030, 738, 698 cm<sup>-1</sup>. HRMS (ESI-MS) m/z [M+H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>20</sub>NO<sub>2</sub>: 342.1489, found:342.1492.  $[\alpha]^{25}_{D} = -13.3$  (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



(*S*)-3-(Benzo[*b*]thiophen-5-yl)-*N*,3-diphenylpropanamide (Figure 2, compound 11). The title compound was synthesized according to **GP-B** stirring for 63 h from *N*,3-diphenylpropanamide and 5-bromobenzo[*b*]thiophene. The product was purified by PTLC on silica gel (Dichloromethane). White solid.

(S)-L: 29 mg, 41% yield, 92% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL AD-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 24.7 min (minor), 27.0 min (major).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.79 (d, *J* = 8.4 Hz, 1H), 7.73 (s, 1H), 7.42 (d, *J* = 5.4 Hz, 1H), 7.30 (d, *J* = 4.4 Hz, 4H), 7.28 – 7.19 (m, 7H), 7.05 (t, *J* = 6.8 Hz, 1H), 7.01 (brs, 1H), 4.78 (t, *J* = 7.7 Hz, 1H), 3.14 (d, *J* = 7.7 Hz, 2H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.4, 143.7, 140.0, 139.8, 138.1, 137.5, 128.8, 128.7, 127.8, 126.9, 126.7, 124.5, 124.4, 123.8, 122.7, 122.4, 120.1, 47.3, 44.5.

FT-IR (film): 3288, 2923, 1656, 1599, 1543, 1497, 1443, 1307, 1080, 754, 695 cm<sup>-1</sup>.

HRMS (ESI-MS) m/z [M+H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>20</sub>NOS: 358.1260, found: 358.1260. [ $\alpha$ ]<sup>25</sup><sub>D</sub> = -11.6 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



(1*S*,2*R*,5*R*)-5-Isopropyl-2-methylcyclohexyl 4-((*S*)-3-oxo-1-phenyl-3-(phenylamino)propyl)benzoate (Figure 2, compound 12). The title compound was synthesized according to **GP-B** from *N*,3-diphenylpropanamide and (1*S*,2*R*,5*R*)-5-isopropyl-2methylcyclohexyl 4-bromobenzoate prepared by known procedure.<sup>7</sup> The product was purified by PTLC on silica gel (1:3 EtOAc/Petroleum ether). White solid.

(*S*)-L: 52 mg, 54% yield, 95:5 dr.

HPLC analysis: The dr was determined via HPLC on a CHIRALCEL OD-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 11.5 min (major), 15.1 min (minor).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.96 (d, *J* = 8.2 Hz, 2H), 7.35 – 7.28 (m, 5H), 7.27 – 7.15 (m, 6H), 7.06 (t, *J* = 7.2 Hz, 1H), 4.90 (td, *J* = 10.9, 4.4 Hz, 1H), 4.72 (t, *J* = 7.6 Hz, 1H), 3.09 (d, *J* = 7.6 Hz, 2H), 2.11 – 2.03 (m, 1H), 1.98 – 1.87 (m, 1H), 1.75 – 1.66 (m, 2H), 1.58 – 1.46 (m, 2H), 1.16 – 1.00 (m, 2H), 0.94 – 0.86 (m, 7H), 0.76 (d, *J* = 6.9 Hz, 3H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.9, 165.9, 148.7, 142.8, 137.5, 130.0, 129.3, 128.9, 128.8, 127.7, 127.7, 126.9, 124.4, 120.1, 74.8, 47.3, 47.2, 43.8, 41.0, 34.3, 31.4, 26.5, 23.6, 22.0, 20.7, 16.5.

FT-IR (film): 3314, 3061, 2955, 1712, 1663, 1600, 1541, 1498, 1443, 1276, 1107, 752, 696 cm<sup>-1</sup>. HRMS (ESI-MS) m/z [M+Na]<sup>+</sup> calcd for C<sub>32</sub>H<sub>37</sub>NO<sub>3</sub>Na: 506.2666, found: 506.2670. [ $\alpha$ ]<sup>25</sup><sub>D</sub> = -54.7 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



(*R*)-3-(4-Methoxyphenyl)-*N*-phenyl-3-(4-(trifluoromethyl)phenyl)propanamide (Figure 3, compound 13). The title compound was synthesized according to GP-B from 3-(4-methoxyphenyl)-*N*-phenylpropanamide and 4-bromobenzotrifluoride. The product was purified by PTLC on silica gel (Dichloromethane). White solid.

(*S*)-L: 53 mg, 66% yield, 93% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 15.8 min (major), 18.2 min (minor).

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.49 (d, *J* = 8.1 Hz, 2H), 7.44 (brs, 1H), 7.35 – 7.27 (m, 4H), 7.25 – 7.18 (m, 2H), 7.11 (d, *J* = 8.5 Hz, 2H), 7.06 (t, *J* = 7.3 Hz, 1H), 6.81 (d, *J* = 8.5 Hz, 2H), 4.65 (t, *J* = 7.7 Hz, 1H), 3.74 (s, 3H), 3.01 (d, *J* = 7.7 Hz, 2H).

<sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) δ –62.4 (s, 3F).

<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  169.1, 158.5, 148.0, 137.4, 134.6, 128.9, 128.74 (q, *J*<sub>C-F</sub> = 32.5 Hz), 128.67, 127.9, 125.51 (q, *J*<sub>C-F</sub> = 3.7 Hz), 124.5, 124.11 (q, *J*<sub>C-F</sub> = 272.4 Hz), 120.2, 114.2, 55.2, 46.2, 43.8. FT-IR (film): 3297, 3062, 2933, 1659, 1600, 1548, 1512, 1444, 1326, 1251, 1116, 830, 757 cm<sup>-1</sup>. HRMS (ESI-MS) *m*/*z* [M+Na]<sup>+</sup> calcd for C<sub>23</sub>H<sub>20</sub>F<sub>3</sub>NO<sub>2</sub>Na: 422.1338, found: 422.1339. [ $\alpha$ ]<sup>25</sup><sub>D</sub> = +8.7 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



(*R*)-3-(3-Chlorophenyl)-*N*-phenyl-3-(4-(trifluoromethyl)phenyl)propanamide (Figure 3, compound 14). The title compound was synthesized according to GP-B from 3-(3-chlorophenyl)-*N*-phenylpropanamide and 4-bromobenzotrifluoride. The product was purified by PTLC on silica gel (5:1 Dichloromethane/Petroleum ether). White solid.

(S)-L: 36 mg, 45% yield, 88% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 12.8 min (major), 17.9 min (minor).

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.55 (d, *J* = 8.0 Hz, 2H), 7.39 – 7.31 (m, 4H), 7.30 – 7.27 (m, 1H), 7.24 – 7.18 (m, 3H), 7.16 – 7.07 (m, 3H), 4.74 (t, *J* = 7.6 Hz, 1H), 3.05 (d, *J* = 7.6 Hz, 2H).

<sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) δ -62.5 (s, 3F).

 $^{13}\mathrm{C}$  NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  168.3, 146.9, 144.7, 137.2, 134.7, 130.1, 129.23 (q,  $J_{\mathrm{C-F}}$  = 33.0 Hz), 129.0, 128.1, 127.8, 127.3, 126.1, 125.76 (q,  $J_{\mathrm{C-F}}$  = 3.8 Hz), 124.7, 124.03 (q,  $J_{\mathrm{C-F}}$  = 272.7 Hz), 120.1, 46.5, 43.4.

FT-IR (film): 3296, 2926, 1660, 1597, 1553, 1499, 1444, 1326, 1126, 1070, 759, 695 cm<sup>-1</sup>. HRMS (ESI-MS) m/z [M+H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>18</sub>ClF<sub>3</sub>NO: 404.1024, found: 404.1020. [ $\alpha$ ]<sup>25</sup><sub>D</sub> = +1.3 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



(*S*)-*N*-(4-Cyanophenyl)-3-phenyl-3-(4-(trifluoromethyl)phenyl)propanamide (Figure 3, compound 15). The title compound was synthesized according to GP-B from *N*-(4-cyanophenyl)-3-phenylpropanamide and 4-bromobenzotrifluoride. The product was purified by PTLC on silica gel (Dichloromethane). White solid.

(S)-L: 43 mg, 54% yield, 90%.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (25.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 8.7 min (major), 12.2 min (minor).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.59 – 7.51 (m, 4H), 7.50 – 7.44 (m, 2H), 7.38 (d, *J* = 8.2 Hz, 2H), 7.35 – 7.29 (m, 2H), 7.28 – 7.21 (m, 4H), 4.72 (t, *J* = 7.6 Hz, 1H), 3.20 – 3.08 (m, 2H).

<sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) δ -62.5 (s, 3F).

<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 169.3, 147.3, 142.3, 141.6, 133.2, 129.05 (q, *J*<sub>C-F</sub> = 32.5 Hz), 128.98, 128.0, 127.6, 127.2, 125.66 (q, *J*<sub>C-F</sub> = 3.8 Hz), 124.03 (q, *J*<sub>C-F</sub> = 272.6 Hz), 119.6, 118.8, 107.1, 46.9, 43.7. FT-IR (film): 3324, 2927, 2227, 1675, 1595, 1526, 1453, 1409, 1325, 1164, 1018, 837, 700 cm<sup>-1</sup>. HRMS (ESI-MS) *m*/*z* [M+Na]<sup>+</sup> calcd for C<sub>23</sub>H<sub>17</sub>F<sub>3</sub>N<sub>2</sub>ONa: 417.1185, found: 417.1185. [α]<sup>25</sup><sub>D</sub> = +0.9 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



(*S*)-3-Phenyl-*N*-(3-(trifluoromethyl)phenyl)-3-(4-(trifluoromethyl)phenyl)propanamide (Figure 3, compound 16). The title compound was synthesized according to GP-B from 3phenyl-*N*-(3-(trifluoromethyl)phenyl)propanamide and 4-bromobenzotrifluoride. The product was purified by PTLC on silica gel (Dichloromethane). White solid.

(S)-L: 67 mg, 77% yield, 92% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 8.3 min (major), 12.4 min (minor).

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.58 (s, 1H), 7.56 – 7.48 (m, 3H), 7.40 – 7.33 (m, 4H), 7.32 – 7.27 (m, 3H), 7.27 – 7.21 (m, 3H), 4.72 (t, *J* = 7.7 Hz, 1H), 3.19 – 2.99 (m, 2H).

<sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) δ -62.5 (s, 3F), -62.8 (s, 3F).

<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 169.3, 147.4, 142.3, 137.8, 131.29 (q, *J*<sub>C-F</sub> = 32.6 Hz), 129.5, 129.0 (q, *J*<sub>C-F</sub> = 32.6 Hz), 128.97, 128.0, 127.6, 127.2, 125.64 (q, *J*<sub>C-F</sub> = 3.7 Hz), 124.05 (q, *J*<sub>C-F</sub> = 272.5 Hz), 123.69 (q, *J*<sub>C-F</sub> = 273.0 Hz), 123.1, 121.09 (q, *J*<sub>C-F</sub> = 3.5 Hz), 116.73 (q, *J*<sub>C-F</sub> = 3.5 Hz), 46.9, 43.6.

FT-IR (film): 3297, 2927, 1663, 1618, 1557, 1493, 1449, 1328, 1126, 1018, 798, 698 cm<sup>-1</sup>. HRMS (ESI-MS) m/z [M+H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>18</sub>F<sub>6</sub>NO: 438.1287, found: 438.1291. [ $\alpha$ ]<sup>25</sup><sub>D</sub> = +0.2 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



(*S*)-*N*-(3-Methoxyphenyl)-3-phenyl-3-(4-(trifluoromethyl)phenyl)propanamide (Figure 3, compound 17). The title compound was synthesized according to **GP-B** from *N*-(3-methoxyphenyl)-3-phenylpropanamide and 4-bromobenzotrifluoride. The product was purified by PTLC on silica gel (Dichloromethane). White solid.

(S)-L: 17 mg, 21% yield, 86% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (25.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 10.2 min (major), 12.3 min (minor).

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.54 (d, *J* = 8.1 Hz, 2H), 7.38 (d, *J* = 8.0 Hz, 2H), 7.34 – 7.28 (m, 2H), 7.26 – 7.21 (m, 3H), 7.15 (t, *J* = 8.1 Hz, 1H), 7.09 (s, 1H), 7.03 (brs, 1H), 6.77 (d, *J* = 7.9 Hz, 1H), 6.64 (d, *J* = 8.1 Hz, 1H), 4.74 (t, *J* = 7.6 Hz, 1H), 3.76 (s, 3H), 3.15 – 3.00 (m, 2H).

<sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) δ -62.5 (s, 3F).

 $^{13}\text{C}$  NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  168.8, 160.1, 147.6, 142.6, 138.6, 129.6, 128.91 (q,  $J_{\text{C-F}}$  = 32.6 Hz), 128.92, 128.1, 127.7, 127.1, 125.61 (q,  $J_{\text{C-F}}$  = 3.7 Hz), 124.09 (q,  $J_{\text{C-F}}$  = 272.4 Hz), 112.1, 110.3, 105.8, 55.3, 46.9, 43.9.

FT-IR (film): 3295, 3059, 2925, 1660, 1609, 1546, 1493, 1454, 1326, 1164, 1069, 699 cm<sup>-1</sup>. HRMS (ESI-MS) m/z [M+Na]<sup>+</sup> calcd for C<sub>23</sub>H<sub>20</sub>F<sub>3</sub>NO<sub>2</sub>Na: 422.1338, found: 422.1339. [ $\alpha$ ]<sup>25</sup>D = +0.1 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



(*S*)-1,3-Diphenyl-3-(4-(trifluoromethyl)phenyl)propan-1-one (Figure 3, compound 18). The known compound<sup>8</sup> was synthesized according to **GP-B** from 1,3-diphenylpropan-1-one prepared by the reported literature,<sup>9</sup> and 4-bromobenzotrifluoride. The product was purified by PTLC on silica gel (1:20 EtOAc/Petroleum ether). White solid.

(*S*)-L: 43 mg, 60% yield, 60% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 6.4 min (major), 7.6 min (minor).

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.96 – 7.91 (m, 2H), 7.56 (t, *J* = 7.4 Hz, 1H), 7.52 (d, *J* = 8.1 Hz, 2H), 7.45 (t, *J* = 7.7 Hz, 2H), 7.38 (d, *J* = 8.1 Hz, 2H), 7.32 – 7.27 (m, 2H), 7.27 – 7.23 (m, 2H), 7.22 – 7.17 (m, 1H), 4.89 (t, *J* = 7.3 Hz, 1H), 3.82 – 3.69 (m, 2H).

<sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) δ -62.4 (s, 3F).

<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  197.4, 148.2, 143.3, 136.8, 133.3, 128.8, 128.7, 128.67 (q, *J*<sub>C-F</sub> = 32.3 Hz), 128.2, 128.0, 127.8, 126.8, 125.50 (q, *J*<sub>C-F</sub> = 3.8 Hz), 124.17 (q, *J*<sub>C-F</sub> = 272.5 Hz), 45.7, 44.4. [ $\alpha$ ]<sup>25</sup><sub>D</sub> = +5.8 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



**Ethyl (S)-3-phenyl-3-(4-(trifluoromethyl)phenyl)propanoate (Figure 3, compound 19).** The known compound<sup>10</sup> was synthesized according to **GP-B** from ethyl 3-phenylpropanoate and 4-bromobenzotrifluoride. The product was purified by PTLC on silica gel (1:10 EtOAc/Petroleum ether). Colorless oil.

(S)-L: 16 mg, 25% yield, 41% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (10.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 4.8 min (minor), 5.5 min (major).

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.54 (d, *J* = 8.1 Hz, 2H), 7.36 (d, *J* = 8.1 Hz, 2H), 7.33 – 7.26 (m, 2H), 7.24 – 7.19 (m, 3H), 4.61 (t, *J* = 8.0 Hz, 1H), 4.04 (q, *J* = 7.1 Hz, 2H), 3.06 (d, *J* = 8.0 Hz, 2H), 1.12 (t, *J* = 7.1 Hz, 3H).

<sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) δ -62.5 (s, 3F).

<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  171.4, 147.5, 142.5, 128.87 (q, *J*<sub>C-F</sub> = 32.5 Hz), 128.7, 128.1, 127.6, 126.9, 125.51 (q, *J*<sub>C-F</sub> = 3.7 Hz), 124.14 (q, *J*<sub>C-F</sub> = 272.2 Hz), 60.6, 46.9, 40.5, 14.0.

 $[\alpha]^{25}D = -0.9$  (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



(*S*)-*N*,4-Diphenyl-4-(4-(trifluoromethyl)phenyl)butanamide (Figure 3, compound 20). The title compound was synthesized according to **GP-B** from *N*,4-diphenylbutanamide and 4-bromobenzotrifluoride. The product was purified by PTLC on silica gel (5:1 Dichloromethane/Petroleum ether). White solid.

(S)-L: 41 mg, 53% yield, 65% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 16.2 min (minor), 24.7 min (major).

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.53 (d, *J* = 8.1 Hz, 2H), 7.47 (d, *J* = 7.9 Hz, 2H), 7.36 (d, *J* = 7.9 Hz, 2H), 7.34 – 7.28 (m, 4H), 7.25 – 7.21 (m, 3H), 7.18 (brs, 1H), 7.11 (t, *J* = 7.4 Hz, 1H), 4.05 (t, *J* = 7.9 Hz, 1H), 2.49 (q, *J* = 7.5 Hz, 2H), 2.35 – 2.21 (m, 2H).

<sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) δ –62.4 (s, 3F).

<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 170.4, 148.3, 143.0, 137.7, 129.0, 128.8, 128.68 (q, J<sub>C-F</sub> = 32.7 Hz),
128.1, 127.9, 126.8, 125.49 (q, J<sub>C-F</sub> = 3.7 Hz), 124.3, 124.17 (q, J<sub>C-F</sub> = 272.4 Hz), 119.8, 50.1, 35.5, 30.6. FT-IR (film): 3304, 2927, 1660, 1600, 1545, 1499, 1443, 1326, 1123, 1018, 757, 700 cm<sup>-1</sup>. HRMS (ESI-MS) *m*/*z* [M+H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>21</sub>F<sub>3</sub>NO: 384.1570, found: 384.1572. [α]<sup>25</sup><sub>D</sub> = +0.3 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



**(S)-4-(1-Phenylethyl)benzonitrile (Figure 3, compound 21).** The known compound<sup>4</sup> was synthesized according to **GP-B** from ethylbenzene and 4-bromobenzonitrile. The product was purified by PTLC on silica gel (1:8 EtOAc/Petroleum ether). Colorless oil.

(S)-L: 28 mg, 68% yield, 44% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ-3 column (1.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 21.9 min (major), 23.7 min (minor).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.60 – 7.54 (m, 2H), 7.35 – 7.28 (m, 4H), 7.25 – 7.16 (m, 3H), 4.20 (q, *J* = 7.2 Hz, 1H), 1.65 (d, *J* = 7.2 Hz, 3H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 151.9, 144.7, 132.2, 128.6, 128.4, 127.5, 126.6, 119.0, 109.9, 44.9, 21.4.

 $[\alpha]^{25}D = +3.0$  (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).



**Methyl (S)-4-(1-phenylpropyl)benzoate (Figure 3, compound 22).** The known compound<sup>4</sup> was synthesized according to **GP-B** from propylbenzene and methyl 4-bromobenzoate. The product was purified by PTLC on silica gel (1:8 EtOAc/Petroleum ether). Colorless oil.

(*S*)-L: 26 mg, 51% yield, 34% ee.

HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD-3 column (1.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (*S*)-L: 7.5 min (major), 8.3 min (minor).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98 (d, *J* = 8.3 Hz, 2H), 7.39 – 7.28 (m, 4H), 7.28 – 7.19 (m, 3H), 3.92 (s, 3H), 3.88 (t, *J* = 7.8 Hz, 1H), 2.13 (p, *J* = 7.3 Hz, 2H), 0.94 (t, *J* = 7.3 Hz, 3H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.1, 150.5, 144.2, 129.7, 128.5, 128.0, 127.94, 127.87, 126.3, 53.22, 51.9, 28.3, 12.6.

 $[\alpha]^{25}_{D}$  = +1.7 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).

#### V. Assignment of Absolute Configuration

The stereochemistry of compound **18**,<sup>8</sup> **19**,<sup>10</sup> **21**,<sup>4</sup> and **22**<sup>4</sup> has been established in the literature. As described below, the (*S*) configuration was assigned for each compound by comparison with the published HPLC analysis and optical rotation.

#### Compound 18:

#### **Optical rotation:**

 $[\alpha]^{25}_{D} = +5.7 (c \ 1.0, CHCl_3); 60\%$  ee, from (*S*)-L. Lit.<sup>8</sup>:  $[\alpha]^{28}_{D} = +8.4 (c \ 1.0, CHCl_3); 81\%$  ee, for (*S*) configuration.

## HPLC analysis:

6.4 min (major), 7.6 min (minor), CHIRALCEL OD-3 column (15.0% 2-PrOH in hexanes, 1.0 mL/min).

Lit.<sup>8</sup>: 20.2 min (major), 26.0 min (minor), for (*S*) configuration, CHIRALCEL OD-H column (1.0% 2-PrOH in hexanes, 0.8 mL/min).

## Compound 19:

#### **Optical rotation:**

 $[\alpha]^{25_{D}} = -1.0$  (*c* 1.0, CHCl<sub>3</sub>); 41% ee, from (*S*)-L. Lit.<sup>10</sup>:  $[\alpha]^{25_{D}} = -2.3$  (*c* 0.991, CHCl<sub>3</sub>); 88% ee, for (*S*) configuration.

## HPLC analysis:

4.8 min (minor), 5.5 min (major). CHIRALCEL OD-3 column (10.0% 2-PrOH in hexanes, 1.0 mL/min).

Lit.<sup>10</sup>: 7.5 min (minor), 9.2 min (major) for (*S*) configuration, CHIRALCEL OD-H column (1.0% 2-PrOH in hexanes, 1.0 mL/min)

## Compound 21:

## **Optical rotation:**

 $[\alpha]^{20}$ D = +2.8 (*c* 1.0, CHCl<sub>3</sub>); 44% ee, from (*S*)-L.

Lit.<sup>4</sup>:  $[\alpha]^{20}D = +5.9$  (*c* 0.74, CHCl<sub>3</sub>); 77% ee, for (*S*) configuration.

## HPLC analysis:

21.9 min (major), 23.7 min (minor), CHIRALCEL OJ-3 column (1.0% 2-PrOH in hexanes, 1.0 mL/min).

Lit.<sup>4</sup>: 18.8 min (major), 20.1 min (minor), for (*S*) configuration, CHIRALCEL OJ-H column (2.0% 2-PrOH in hexanes, 1.0 mL/min).

#### Compound 22:

#### **Optical rotation:**

 $[\alpha]^{20_D}$  = +1.5 (*c* 1.0, CHCl<sub>3</sub>); 34% ee, from (*S*)-L. Lit.<sup>4</sup>:  $[\alpha]^{20_D}$  = +2.7 (*c* 0.85, CHCl<sub>3</sub>); 80% ee, for (*S*) configuration.

#### **HPLC** analysis:

7.5 min (major), 8.3 min (minor), CHIRALCEL OD-3 column (1.0% 2-PrOH in hexanes, 1.0 mL/min).

Lit.<sup>4</sup>: 6.6 min (major), 7.0 min (minor) for (*S*) configuration, CHIRALCEL OD-H column (2.0% 2-PrOH in hexanes, 1.0 mL/min).

#### VI. References

1. Nozawa-Kumada, K.; Saga, S.; Matsuzawa, Y.; Hayashi, M.; Shigeno, M.; Kondo, Y. Coppercatalyzed oxidative benzylic C(sp<sup>3</sup>)–H cyclization for the synthesis of β-lactams. *Chem. Eur. J.* **2020**, *26*, 4496-4499.

2. Poremba, K. E.; Kadunce, N. T.; Suzuki, N.; Cherney, A. H.; Reisman, S. E. Nickel-catalyzed asymmetric reductive cross-coupling to access 1,1-diarylalkanes. *J. Am. Chem. Soc.* **2017**, *139*, 5684-5687.

3. Mao, J.; Liu, F.; Wang, M.; Wu, L.; Zheng, B.; Liu, S.; Zhong, J.; Bian, Q.; Walsh, P. J. Cobaltbisoxazoline-catalyzed asymmetric kumada cross-coupling of racemic *α*-bromo esters with aryl grignard reagents. *J. Am. Chem. Soc.* **2014**, *136*, 17662-17668.

4. Cheng, X.; Lu, H.; Lu, Z. Enantioselective benzylic C–H arylation via photoredox and nickel dual catalysis. *Nat. Commun.* **2019**, *10*, 3549-3555.

5. Holder, J. C.; Zou, L.; Marziale, A. N.; Liu, P.; Lan, Y.; Gatti, M.; Kikushima, K.; Houk, K. N.; Stoltz, B. M. Mechanism and enantioselectivity in palladium-catalyzed conjugate addition of arylboronic acids to β-substituted cyclic enones: insights from computation and experiment. *J. Am. Chem. Soc.* **2013**, *135*, 14996-15007.

6. Rossolini, T.; Leitch, J. A.; Grainger, R.; Dixon, D. J. Photocatalytic three-component umpolung synthesis of 1,3-diamines. *Org. Lett.* 2018, *20*, 6794-6798.

7. Shen, Y.; Gu, Y.; Martin, R. Sp<sup>3</sup> C-H Arylation and alkylation enabled by the synergy of triplet excited ketones and nickel catalysts. *J. Am. Chem. Soc.* **2018**, *140*, 12200-12209.

8. Casotti, G.; Rositano, V.; Iuliano, A. Enantioselective conjugate addition of stabilized arylzinc iodide to enones: an improved protocol of the Hayashi reaction. *Adv. Synth. Catal.* **2021**, *363*, 1126-1131.

9. Sankar, V.; Kathiresan, M.; Sivakumar, B. Mannathan, S. Zinc-catalyzed *N*-alkylation of aromatic amines with alcohols: A ligand-free approach. *Adv. Synth. Catal.* **2020**, *362*, 4409-4414.

10. Zullo, V.; Iuliano, A. Rh-catalyzed asymmetric conjugate addition of arylboronic acids to 3-arylpropenoates: enantioselective synthesis of (*R*)-tolterodine. *Eur. J. Org. Chem.* **2019**, 1377-1384.

#### VII. <sup>1</sup>H-NMR and <sup>13</sup>C-NMR Spectra; Stereoselectivity Analysis

Figure S-1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), and <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) spectrum of (S)-L.



**Figure S-2.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) spectrum of **1**.



0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -2( f1 (ppm)





## S-26





## **Figure S-6.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) spectrum of **5**. PhHN Ph Figture 2, (5) 3.93 6.77 1.98 1.98 1.98 2.01 $1.00_{\rm H}$ $2.04_{\mathrm{H}}$ 1.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 -1 fl (ppm) 143.04 142.07 137.42 132.41 128.90 128.90 128.76 128.75 128.75 128.75 128.75 128.76 127.65 127.65 127.43 127.65 127.43 127.44 127.43 12 -169.0477.32 77.00 76.68 ~ 46.64 ~ 44.05 170 160 150 140 130 120 110 100 80 70 60 50 40 30 20 10 (







#### S-32



# 






**Figure S-14.** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>), <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) spectrum of **13**.



0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 fl (ppm)



Figure S-15. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>), <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (126 MHz,



-90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 fl (ppm) 0 -10 -20 -30 -40 -50 -60 -70 -80



Figure S-16. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) spectrum of 15.





Figure S-17. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (126 MHz,





Figure S-18. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>), <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (126 MHz,







Figure S-19. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>), <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (126 MHz,

CDCl<sup>3</sup>) spectrum of **18**.





**Figure S-20.** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>), <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) spectrum of **19**.

4 ~ ~ ~ - ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	∞ − 6 9 9 4 7 Γ 9	0 10 70
000000000000000	$\circ \circ $	
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	444444	
		$\checkmark$



0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 fl (ppm)



**Figure S-21.** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>), <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) spectrum of **20**.



0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -19 fl (ppm)



Figure S-22. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) spectrum of 21.





## **Stereoselectivity Analysis**















rac-




























